Related Experiment Video
Updated: Nov 23, 2025
07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.8K
Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors
Steve Biko Otieno1,2,3, Syed Nasir1,3, Alva Weir1,2
1The University of Tennessee Health Science Center, Department of Hematology/Oncology, 19 S. Manassas, Memphis, TN 38103, USA.
Case Reports in Hematology
|December 31, 2020
Summary
BRAFV600E mutations occur in 4-10% of multiple myeloma cases and may cause resistance to standard therapies. Targeted BRAF therapy in a relapsed/refractory patient showed 8.5 months of progression-free survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Multiple myeloma is a hematologic malignancy with poor prognosis in relapsed/refractory cases.
- The mitogen-activated protein kinase (MAPK) pathway is crucial in multiple myeloma pathogenesis.
- BRAFV600E mutations activate the MAPK pathway, driving oncogenesis and potentially conferring resistance to proteasome inhibitors.
Observation:
- This report details a patient with relapsed and refractory multiple myeloma harboring the BRAFV600E mutation.
- BRAFV600E-directed therapy is not currently approved for multiple myeloma treatment.
- The BRAFV600E mutation is found in 4-10% of multiple myeloma patients.
Findings:
- The patient received BRAF-targeted therapy.
- The patient achieved a progression-free survival (PFS) of 8.5 months.
Implications:
- BRAF-targeted therapy shows potential in a subset of multiple myeloma patients with BRAFV600E mutations.
- Further research is warranted to explore BRAF-directed therapies in multiple myeloma.
- Understanding the role of BRAFV600E mutations may guide personalized treatment strategies for multiple myeloma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:07MAPK Signaling Cascades
7.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K